ab16895 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab16895 は 20 報の論文で使用されています。

  • Avallone G  et al. Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma. Vet Pathol 53:773-80 (2016). PubMed: 26993784
  • Mikawa T  et al. Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. J Cell Biol 204:729-45 (2014). PubMed: 24567357
  • Lee JH  et al. Protein grafting of p53TAD onto a leucine zipper scaffold generates a potent HDM dual inhibitor. Nat Commun 5:3814 (2014). PubMed: 24804811
  • Drosten M  et al. Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proc Natl Acad Sci U S A 111:15155-60 (2014). PubMed: 25288756
  • Cubillos-Rojas M  et al. The E3 ubiquitin protein ligase HERC2 modulates the activity of tumor protein p53 by regulating its oligomerization. J Biol Chem 289:14782-95 (2014). PubMed: 24722987
  • Malek MH  et al. Similar skeletal muscle angiogenic and mitochondrial signalling following 8 weeks of endurance exercise in mice: discontinuous versus continuous training. Exp Physiol 98:807-18 (2013). Mouse . PubMed: 23180811
  • Ross AP  et al. A mutation in mouse Pak1ip1 causes orofacial clefting while human PAK1IP1 maps to 6p24 translocation breaking points associated with orofacial clefting. PLoS One 8:e69333 (2013). IP ; Mouse . PubMed: 23935987
  • Maglic D  et al. Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene 32:4120-9 (2013). WB ; Human . PubMed: 23045280
  • Fukawa T  et al. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas. Cancer Res 72:5867-77 (2012). PubMed: 23019224
  • Bernard H  et al. The p53 isoform, ?133p53a, stimulates angiogenesis and tumour progression. Oncogene : (2012). Human . PubMed: 22733133
  • Villalonga-Planells R  et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6:e18588 (2011). WB ; Human . PubMed: 21483692
  • Sashida G  et al. The mef/elf4 transcription factor fine tunes the DNA damage response. Cancer Res 71:4857-65 (2011). WB ; Mouse . PubMed: 21616937
  • Malek R  et al. The p53 Inhibitor MDM2 Facilitates Sonic Hedgehog-Mediated Tumorigenesis and Influences Cerebellar Foliation. PLoS One 6:e17884 (2011). WB ; Mouse . PubMed: 21437245
  • Llanos S & Serrano M Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle 9:4005-12 (2010). WB ; Human . PubMed: 20935493
  • Salem MM  et al. Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage. FASEB J 23:3790-807 (2009). IHC-Fr ; Human . PubMed: 19641144
  • Sashida G  et al. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol 29:3687-99 (2009). PubMed: 19380490
  • Llanos S  et al. MSK2 inhibits p53 activity in the absence of stress. Sci Signal 2:ra57 (2009). WB ; Human . PubMed: 19797274
  • Maimets T  et al. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene 27:5277-87 (2008). WB ; Human . PubMed: 18521083
  • Efeyan A  et al. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 67:7350-7 (2007). PubMed: 17671205
  • Reagan-Shaw S  et al. Enhancement of UVB radiation-mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes. Mol Cancer Ther 5:418-29 (2006). PubMed: 16505117

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"